



Figure 1: Rituximab Crystals



10034950, 122601

Figure 2: Infliximab Crystals



10034950.122601

Figure 3: Rituximab Cube-shaped Crystals




10234950-122601

Figure 4: Rituximab Small Needle-like Crystals




10034950.122601

Figure 5: Trastuzumab Crystals



10034950-122601

Figure 6: Trastuzumab Long Needle-like Crystals



10034950.1.00001

Figure 8: Crystallized Rituximab-Induced Direct Cytotoxicity




Figure 9: Crystallized Rituximab-Induced Complement-Dependent Cytotoxicity




Figure 10: Analysis of Dissolved Rituximab Crystals




Figure 11: Analysis of Dissolved Trastuzumab Crystals




Figure 12: Stability of Rituximab in the Crystalline Form

10034950.122601



Figure 13: Crystalline Trastuzumab after treatment with Acetone




Figure 14: Soluble Trastuzumab after treatment with Acetone




Figure 15: Bioavailability of Crystalline Trastuzumab Administered Intravenously (I.V.) or Subcutaneously (S.C.)

